% | $
Quotes you view appear here for quick access.

Trius Therapeutics, AŞ Message Board

  • brandonuk03 brandonuk03 Dec 4, 2012 11:31 AM Flag

    Thoughts from Piper Jaffray webcast

    Listened to the webcast and several things stood out:

    1) Expect better results from ESTABLISH-2 due to IV bioavailability being higher than oral. Patients at sites in Europe tend to have larger lesions (due to delay in treatment by Europeans) and from previous data analysis, Tedizolid (TZD) shows better results in these patients than Zyvox. Jeff Stein said this trial is pretty much "de-risked" from an investment standpoint.

    2) Jeff Stein CEO said, "we are in partnership discussions." He recently posted on twitter that management has been undergoing partnership training seminars via a professor at Harvard. Eluded that big pharma has high interest and that there is no hurry to partner until after ESTABLISH-2 data is released. They can command better terms with great results that are expected from this trial. To note, Trius has a ATM (at the market) financing deal with that will sell up to $25 million dollars worth of stock at Trius' discretion. This also gives flexibility for management not to feel rushed to partner.

    3) Trial to be completed by December with top-line data by March/April. NDA filing in Q3 (July-Sept) with a 6-8 month review under GAIN Act placing approval at the beginning of 2014.